Insider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells $22,160.37 in Stock

Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset sold 3,207 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $6.91, for a total transaction of $22,160.37. Following the sale, the executive vice president now owns 199,099 shares of the company’s stock, valued at $1,375,774.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Valerie Morisset also recently made the following trade(s):

• On Monday, July 15th, Valerie Morisset sold 42,377 shares of Eliem Therapeutics stock. The stock was sold at an average price of $7.01, for a total transaction of $297,062.77.
• On Thursday, July 11th, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The stock was sold at an average price of $7.11, for a total transaction of $355,500.00.
• On Tuesday, July 9th, Valerie Morisset sold 5,931 shares of Eliem Therapeutics stock. The stock was sold at an average price of $6.66, for a total transaction of $39,500.46.
• On Friday, July 5th, Valerie Morisset sold 12,342 shares of Eliem Therapeutics stock. The stock was sold at an average price of $7.06, for a total transaction of $87,134.52.
• On Wednesday, July 3rd, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The stock was sold at an average price of $6.76, for a total transaction of $338,000.00.

Eliem Therapeutics Stock Up 7.8 %

NASDAQ ELYM opened at $7.30 on Monday. The stock has a market capitalization of $217.19 million, a PE ratio of -13.77 and a beta of -0.33. The company has a 50 day moving average price of $7.66 and a two-hundred day moving average price of $4.99. Eliem Therapeutics, Inc. has a 12-month low of $2.35 and a 12-month high of $11.55.

Eliem Therapeutics (NASDAQ:ELYM) last posted its earnings results on Wednesday, May 15th. The company reported ($0.06) earnings per share (EPS) for the quarter.

Institutional Trading of Eliem Therapeutics

A hedge fund recently bought a new stake in Eliem Therapeutics stock. Cerity Partners LLC bought a new stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 13,821 shares of the company’s stock, valued at approximately $37,000. Cerity Partners LLC owned about 0.05% of Eliem Therapeutics as of its most recent SEC filing. 69.76% of the stock is owned by institutional investors.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.